If your provider documents that semaglutide is being prescribed to manage prediabetes, insulin resistance, hypertension, or another diagnosed condition, the medication is being used to treat a disease, which aligns with the IRSs definition of a qualified medical expense
It also suggests investors are starting to price in the next leg of growth beyond the initial GLP-1 wavewhether through label expansions, oral GLP-1/GIP programs, or adjacent cardiometabolic indications
While many patients experience improved wellbeing during treatment, some may notice emotional changes linked to reduced appetite, hormone shifts, physical adjustment, or changing eating habits
Whats the difference between CJC-1295 with DAC and without DAC
Clinician review is required, and if appropriate, prescription will be submitted
Age takes a toll on human exercise capacity